Feed KTTA
KT

Pasithea Therapeutics Corp. KTTA · NASDAQ

$0.43 +4.80% (+$0.02)

Market cap
$13.7M
Enterprise value
-$45.7B
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/FCF
-
EV/EBITDA
-
ROIC
-0.0%
Gross margin
-
Net margin
-
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
0.29
Free float
96.4%

About the company

Pasithea Therapeutics Corp. (KTTA) is an American biotechnology company focused on the development and commercialization of new treatments for neurological and psychiatric disorders. With an emphasis on innovative approaches to treating depression, anxiety, and other mental health conditions, Pasithea is a leading player in the field of neuroscience research. The company is known for its strong focus on the research and development of new therapeutic solutions that can improve patients' quality of life. Pasithea Therapeutics also collaborates with academic and scientific institutions to accelerate innovation in its field. Pasithea Therapeutics Corp. (KTTA) shares could be suitable for investors looking to invest in biotechnology and healthcare with the potential for breakthrough discoveries in mental health treatment.

Sector

Healthcare

Industry

Biotechnology

CEO

Tiago Reis Marques

Employees

5

Headquarters

Miami Beach

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.